MSRD 100

Drug Profile

MSRD 100

Alternative Names: MSRD-100

Latest Information Update: 26 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merz Pharmaceuticals
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Atopic dermatitis

Most Recent Events

  • 08 Sep 2016 Merz Pharmaceuticals withdraws two phase III trials for Atopic dermatitis (In infants, In children, In adolescents, In adults) in USA (Topical, Gel) (NCT02677610; NCT02677636)
  • 16 Feb 2016 Clinical trials in Atopic dermatitis in Germany (Topical) before February 2016
  • 16 Feb 2016 Merz Pharmaceuticals plans two phase III trials for Atopic dermatitis (In infants, In children, In adolescents, In adults) in USA (Topical, Gel) (NCT02677610; NCT02677636)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top